**FOI Ref: 6098**

**Category(ies): Clinical - Drugs**

**Subject: Biologic Medications**

**Date Received: 15/11/2021**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| Q1. How many patients were treated in October 2021 (or latest available month) by the dermatology department with the following drugs:   * Abrocitinib (Cibinqo) * Baricitinib (Olumiant) * Bimekizumab (Bimzelx) * Brodalumab (Kyntheum) * Dupilumab (Dupixent) * Ixekizumab (Taltz) * Risankizumab (Skyrizi) * Guselkumab (Tremfya) * Secukinumab (Cosentyx) * Tildrakizumab (Ilumetri) * Tralokinumab (Adtralza) * Ustekinumab (Stelara) | 0  0  0  2  22  3  0  18  20  0  0  12 |
| Q2. How many patients were treated in October 2021 (or latest available month) by the rheumatology department with the following drugs:   * Baricitinib (Olumiant) * Filgotinib (Jyseleca) * Guselkumab (Tremfya) * Ixekizumab (Taltz) * Secukinumab (Cosentyx) * Tofacitinib (Xeljanz) * Upadacitinib (Rinvoq) * Ustekinumab (Stelara) | 14  0  0  0  5  2  0  1 |